ERBB2 and colorectal carcinoma: Since the evaluation criteria of HER2 have not been standardized in CRC and have varied from one study to another, different detection methods, antibodies and evaluation systems used to define HER2 overexpression/amplification may contribute to different HER2 positivity rates (Richman et al. 2016; McKay et al. 2002; Blok et al. 2013; Liu et al. 2020; Lee et al. 2014).